AVRO AVROBIO, Inc. Stock Quote

AVRO [NASD]

Index	-	P/E	-	EPS (ttm)	-3.31	Insider Own	1.30%	Shs Outstand	38.60M	Perf Week	-24.24%
Market Cap	360.14M	Forward P/E	-	EPS next Y	-3.09	Insider Trans	0.37%	Shs Float	32.70M	Perf Month	-25.41%
Income	-119.70M	PEG	-	EPS next Q	-0.76	Inst Own	98.70%	Short Float	11.98%	Perf Quarter	-42.25%
Sales	-	P/S	-	EPS this Y	-24.30%	Inst Trans	0.70%	Short Ratio	5.44	Perf Half Y	-36.99%
Book/sh	6.59	P/B	1.32	EPS next Y	2.20%	ROA	-46.50%	Target Price	-	Perf Year	-44.49%
Cash/sh	6.29	P/C	1.39	EPS next 5Y	-	ROE	-50.00%	52W Range	8.72 - 23.50	Perf YTD	-37.45%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-62.89%	Beta	-
Dividend %	-	Quick Ratio	16.10	Sales past 5Y	-	Gross Margin	-	52W Low	0.00%	ATR	0.79
Employees	121	Current Ratio	16.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	30.25	Volatility	9.57% 7.16%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-1.90%	Profit Margin	-	Rel Volume	0.80	Prev Close	8.98
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 18 BMO	Payout	-	Avg Volume	720.33K	Price	8.72
Recom	2.10	SMA20	-20.90%	SMA50	-25.12%	SMA200	-39.76%	Volume	573,496	Change	-2.90%

Mar-09-21

Initiated

Barclays

Overweight

$23

Mar-02-21

Initiated

Stifel

Hold

$14

Nov-11-20

Initiated

Berenberg

Buy

Mar-31-20

Downgrade

H.C. Wainwright

Buy → Neutral

$13

Jun-27-19

Initiated

Mizuho

Buy

$28

Apr-05-19

Initiated

Janney

Buy

Oct-10-18

Initiated

Guggenheim

Buy

Oct-02-18

Reiterated

H.C. Wainwright

Buy

$47 → $40

Sep-17-18

Initiated

H.C. Wainwright

Buy

$47

Jul-16-18

Initiated

Wells Fargo

Outperform

$40

Jul-16-18

Initiated

Wedbush

Outperform

$38

Jul-16-18

Initiated

Morgan Stanley

Overweight

$37

May-05-21 10:24AM	INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
May-04-21 03:40PM	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire -5.27%
02:30PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of AVROBIO, Inc. (AVRO) Investigation ACCESSWIRE
11:06AM	BREAKING ALERT: Rosen Law Firm Encourages AVROBIO, Inc. Investors with Losses to Inquire About Class Action Investigation AVRO Business Wire
01:56AM	We're Hopeful That AVROBIO (NASDAQ:AVRO) Will Use Its Cash Wisely Simply Wall St.
May-03-21 09:42AM	Avrobio Plans Registration Trial With Kidney Biopsy Endpoint To Support Potential Full Approval Of Fabry Disease Gene Therapy Benzinga -18.84%
07:00AM	AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease Business Wire
Apr-27-21 04:30PM	AVROBIO to Present Clinical and Preclinical Data at the ASGCT 24th Annual Meeting Business Wire
Apr-20-21 12:00PM	AVROBIO, Inc. (AVRO) Upgraded to Buy: What Does It Mean for the Stock? Zacks
Apr-06-21 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire -7.22%
Mar-18-21 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update Business Wire -6.64%
Mar-05-21 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +7.40%
Mar-01-21 07:00AM	AVROBIO Receives Orphan Drug Designation from the European Commission for AVRRD04, an Investigational Gene Therapy for Cystinosis Business Wire
Feb-25-21 07:00AM	AVROBIO to Present at Three Upcoming Investor Conferences in March Business Wire
Feb-08-21 08:07AM	Avrobio Shares Rally On Fabry Disease Gene Therapy Encouraging Benefit In Early-Stage Study Benzinga +12.80%
07:00AM	AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial Business Wire
Feb-05-21 04:05PM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +6.77%
Feb-01-21 07:00AM	AVROBIO Announces Multiple Clinical Data Presentations, Posters and Events at 17th Annual WORLDSymposium 2021 Business Wire
Jan-22-21 07:00AM	AVROBIO to Present at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit Business Wire
Jan-19-21 07:00AM	AVROBIO Announces the Appointment of Diana M. Escolar, M.D. as Chief Medical Officer Business Wire
Jan-08-21 07:00AM	AVROBIO to Present at the ICR Conference 2021 Business Wire
Jan-07-21 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire +5.14%
Dec-16-20 10:46AM	Is AVRO A Good Stock To Buy Now? Insider Monkey +5.00%
Dec-04-20 07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-24-20 04:19PM	AVROBIO Announces Closing of Underwritten Public Offering Business Wire
Nov-19-20 10:06PM	AVROBIO Announces Pricing of Underwritten Public Offering of $75 Million of Common Stock Business Wire
04:09PM	AVROBIO Announces Proposed Public Offering of Common Stock Business Wire
Nov-17-20 07:00AM	AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline Business Wire
Nov-06-20 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Nov-05-20 07:00AM	AVROBIO Reports Third Quarter 2020 Financial Results and Provides Business Update Business Wire -10.50%
06:18AM	Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation Simply Wall St.
Oct-29-20 07:00AM	AVROBIO Receives Orphan Drug Designation from the European Commission for AVRRD01, an Investigational Gene Therapy for Fabry Disease Business Wire
Oct-26-20 07:00AM	AVROBIO to Share Clinical and Pipeline Updates at Virtual R&D Day Business Wire
Oct-21-20 07:00AM	AVROBIO Appoints Dr. Gail Farfel to its Board of Directors Business Wire
Oct-06-20 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Oct-05-20 07:00AM	AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome Business Wire +10.79%
Sep-29-20 10:48AM	AVROBIO's Gaucher Disease Candidate Gets Orphan Drug Status Zacks
Sep-28-20 07:00AM	AVROBIO Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease Business Wire
Sep-25-20 07:00AM	AVROBIO to Present at Two Upcoming Investor Conferences Business Wire
Sep-04-20 07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Sep-03-20 07:00AM	AVROBIO to Present at Three Upcoming Investor Conferences Business Wire
Aug-12-20 09:41AM	Did Hedge Funds Make The Right Call On AVROBIO, Inc. (AVRO) ? Insider Monkey
Aug-07-20 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-06-20 07:00AM	AVROBIO Reports Second Quarter 2020 Financial Results and Provides Business Update Business Wire
Aug-05-20 07:00AM	AVROBIO to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference Business Wire
Jul-27-20 08:23AM	AVROBIO Sees Hammer Chart Pattern: Time to Buy? Zacks +6.18%
Jul-08-20 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jul-06-20 07:00AM	AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials Business Wire
Jun-29-20 07:00AM	AVROBIO Announces the Appointment of Kim Raineri as Chief Manufacturing and Technology Officer Business Wire -5.03%
Jun-24-20 04:16PM	Here is What Hedge Funds Think About AVROBIO, Inc. (AVRO) Insider Monkey -7.71%
May-14-20 07:00AM	AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020 Business Wire -6.99%
May-13-20 07:00AM	AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis Business Wire
May-09-20 08:36AM	We're Not Very Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Rate Simply Wall St.
May-08-20 08:42AM	Why Earnings Season Could Be Great for AVROBIO (AVRO) Zacks
May-07-20 07:00AM	AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update Business Wire
May-06-20 04:05PM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
07:00AM	AVROBIO and Magenta Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate as a Potential Conditioning Regimen for Lentiviral Gene Therapies Business Wire
May-05-20 07:00AM	AVROBIO to Present New Clinical and Preclinical Data at Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 12-15, 2020 Business Wire +15.01%
May-04-20 07:00AM	AVROBIO to Collaborate with Saladax Biomedical on New High-Speed Diagnostic Assay Used with Busulfan Conditioning to Enable Widespread Commercialization of AVROBIOs Proprietary Platform Globally Business Wire
Apr-14-20 08:58AM	Is AVROBIO (AVRO) Stock a Solid Choice Right Now? Zacks +7.47%
Apr-12-20 02:26PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVRO PR Newswire
02:26PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVRO CNW Group
Apr-03-20 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Mar-30-20 04:30PM	AVROBIO Outlines Response to COVID-19 and Current Assessment of Business Impact Business Wire +11.16%
02:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVRO GlobeNewswire
Mar-26-20 07:00AM	AVROBIO to Participate in Upcoming April Investor Conferences Business Wire
Mar-25-20 07:47PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVRO PR Newswire
07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Mar-19-20 12:00PM	AVROBIO, Inc. (AVRO) Upgraded to Buy: What Does It Mean for the Stock? Zacks +31.42%
Mar-17-20 05:58PM	INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire +10.02%
01:57PM	AVRO LOSS NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Announces Investigation of Securities Claims Against AVROBIO, Inc. AVRO Business Wire
12:53PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVROBIO, Inc. - AVRO GlobeNewswire
12:25PM	AVRO Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AVROBIO, Inc. and Encourages Investors to Contact the Firm ACCESSWIRE
Mar-16-20 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update Business Wire -32.26%
Mar-09-20 07:00AM	AVROBIO Receives Orphan Drug Designation from U.S. FDA for AVRRD04 for Cystinosis Business Wire -6.32%
Mar-05-20 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-24-20 07:00AM	AVROBIO to Present at the Cowen and Company 40th Annual Health Care Conference Business Wire
Feb-18-20 04:01PM	AVROBIO Announces Closing of Underwritten Public Offering Business Wire -5.67%
Feb-12-20 10:08PM	AVROBIO Announces Pricing of Underwritten Public Offering of $100 Million of Common Stock Business Wire
04:01PM	AVROBIO Announces Proposed Public Offering of Common Stock Business Wire
Feb-11-20 07:23AM	The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Benzinga
Feb-10-20 04:01PM	AVROBIO Presents Positive Initial Data for its Investigational Cystinosis Program and Plato TM Platform, as well as Positive Data Out to 32 Months for its Ongoing Investigational Fabry Program Business Wire +9.62%
Feb-06-20 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Feb-04-20 07:00AM	AVROBIO Announces Clinical Data Presentation and Multiple Events at WORLDSymposium 2020 Business Wire +11.69%
Jan-14-20 07:00AM	AVROBIO Announces Clinical and Regulatory Progress for Gaucher Disease Program Business Wire
Jan-09-20 04:00PM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Dec-19-19 08:00AM	AVROBIO Announces First Patient Dosed Using plato Platform Business Wire
Dec-16-19 08:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Dec-14-19 07:47PM	Is AVROBIO, Inc. (AVRO) Going to Burn These Hedge Funds? Insider Monkey
Nov-07-19 07:00AM	AVROBIO, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update Business Wire
Nov-06-19 02:31PM	AVROBIO, Inc. (AVRO): Are Hedge Funds Right About This Stock? Insider Monkey
Oct-24-19 07:00AM	AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVRRD02 for the Treatment of Gaucher Disease Business Wire
Oct-22-19 07:00AM	AVROBIO Appoints Holly May as Chief Commercial Officer Business Wire
Oct-16-19 06:02AM	Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation Simply Wall St.
Oct-08-19 07:00AM	AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis Business Wire
Oct-03-19 08:00AM	AVROBIO, Inc. to Present at Chardans 3rd Annual Genetic Medicines Conference Business Wire
Sep-27-19 09:00AM	AVROBIO, Inc. (AVRO) Upgraded to Buy: Here's What You Should Know Zacks -5.53%
Sep-11-19 10:22AM	Moving Average Crossover Alert: AVROBIO Zacks
Aug-29-19 07:00AM	AVROBIO, Inc. to Present at Upcoming Investor Conferences Business Wire
Aug-16-19 08:30AM	AVROBIO Appoints Georgette Verdin as Chief Human Resources Officer Business Wire

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's lead product candidate is AVR-RD-01, a gene therapy which is in ongoing company-sponsored Phase 2 clinical trial and investigator-sponsored Phase 1 clinical trial for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in Phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, which is in preclinical development to treat Pompe disease; AVR-RD-04 that is in investigator-sponsored Phase 1/2 clinical trial to treat cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage to treat Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Donenberg Phillip B.	Director	Feb 17	Buy	11.71	2,000	23,420	2,000	Feb 18 07:06 PM
MACKAY GEOFFREY	President & CEO	Dec 24	Option Exercise	0.41	100,000	41,320	245,123	Dec 28 07:46 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience